Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.

The presence of an epidermal growth factor receptor (EGFR) mutation is associated with higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); however, patients with synchronous brain metastases at diagnosis have generally been excluded from clinical trials. As there is limited clinical evidence and clinical guidelines for managing this patient population, a multidisciplinary group of Spanish medical and radiation oncologists, and neuro-oncologist with expertise treating brain metastases in lung cancer patients met with the aim of reaching and developing an expert opinion consensus on the management of patients with EGFR mutated NSCLC with brain metastases. This consensus contains 26 recommendations and 20 conclusion statements across 21 questions in 7 areas, as well as a first-line treatment algorithm. • This is a multidisciplinary expert opinion of Spanish medical oncologists, oncology radiotherapists, and neuro-oncologist. • We aimed to reach a consensus on the management of NSCLC patients harboring sensitizing EGFR mutations who have synchronous brain metastases. • The paper contains consensus recommendations on management of brain metastases in patients with sensitizing EGFR mutated NSCLC. • The paper offers a review of recent literature in management of brain metastases in cancer patients who harbor sensitizing EGFR mutations. The presence of an epidermal growth factor receptor (EGFR) mutation is associated with higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); however, patients with synchronous brain metastases at diagnosis have generally been excluded from clinical trials. As there is limited clinical evidence for managing this patient population, a multidisciplinary group of Spanish medical and radiation oncologists, and neuro-oncologist with expertise treating brain metastases in lung cancer patients met with the aim of reaching and developing an expert opinion consensus on the management of patients with EGFR mutated NSCLC with brain metastases. This consensus contains 26 recommendations and 20 conclusion statements across 21 questions in 7 areas, as well as a first-line treatment algorithm. [ABSTRACT FROM AUTHOR]